Cecilia Chika Unegbu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cecilia Chika Unegbu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aliaa Mohammed Mahmoud Soliman
Department of Psychology and Counseling, Austin Peay State University, Clarksville, TN, USA
1 shared publication - Aliyu Olanrewaju Olaniyi
Geriatrics, Stepping Hill Hospital, Stockport, GBR
1 shared publication - Damilola Ayodele Ojo
Missouri State University
1 shared publication - Fortune Itoje Ebiala
Department of Microbiology, Faculty of Life Sciences, University Of Benin, Benin City, Edo State, Nigeria
1 shared publication - Kingsley Ugonna Ugoagwu
Department of Immunology, College of Medicine, University of Ibadan, Ibadan, Nigeria
1 shared publication - Modinat Aina Abayomi
Department of Biology, Boston College, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
- 19 September 2025
- Published by Australasia Publishing Group in Australian Journal of Biomedical Research
- Vol. 1 (2) , aubm007
Beyond Inhibition: Emerging Small-Molecule Modalities in Oncology (Molecular Glues, Covalents, and Radiotheranostics)
Background: Small-molecule drugs have transformed oncology, but conventional inhibitors are limited by resistance, restricted target scope, and declining durability. Methods: We reviewed emerging small-molecule modalities—molecular glues, covalent inhibitors, and radiotheranostics—focusing on their mechanisms, clinical applications, and translational challenges. Key clinical trials and representative examples were identified from recent oncology literature. Results: Molecular glues enable targeted degradation of previously undruggable proteins, with clinical success in multiple myeloma (IMiDs). Covalent inhibitors achieve durable suppression of oncogenic drivers such as KRAS^G12C and BTK, as shown in CodeBreaK100 (sotorasib; N=126; ORR 37%). Radiotheranostics combine imaging and therapy, exemplified by VISION (PSMA-617; N=831; OS HR 0.62) and NETTER-1 (Lutathera; N=229; PFS HR 0.21). Collectively, these modalities expand the druggable proteome, improve durability, and advance precision oncology. Conclusion: Emerging small-molecule approaches mark a paradigm shift from inhibition alone to targeted degradation, durable covalent engagement, and diagnostic–therapeutic hybrids. Future priorities include improving selectivity, biomarker integration, scalable manufacturing, and equitable global access.
- 19 September 2025
- Published by Australasia Publishing Group in Australian Journal of Biomedical Research
- Vol. 1 (2) , aubm007
Open AccessBeyond Inhibition: Emerging Small-Molecule Modalities in Oncology (Molecular Glues, Covalents, and Radiotheranostics)
Background: Small-molecule drugs have transformed oncology, but conventional inhibitors are limited by resistance, restricted target scope, and declining durability. Methods: We reviewed emerging small-molecule modalities—molecular glues, covalent inhibitors, and radiotheranostics—focusing on their mechanisms, clinical applications, and translational challenges. Key clinical trials and representative examples were identified from recent oncology literature. Results: Molecular glues enable targeted degradation of previously undruggable proteins, with clinical success in multiple myeloma (IMiDs). Covalent inhibitors achieve durable suppression of oncogenic drivers such as KRAS^G12C and BTK, as shown in CodeBreaK100 (sotorasib; N=126; ORR 37%). Radiotheranostics combine imaging and therapy, exemplified by VISION (PSMA-617; N=831; OS HR 0.62) and NETTER-1 (Lutathera; N=229; PFS HR 0.21). Collectively, these modalities expand the druggable proteome, improve durability, and advance precision oncology. Conclusion: Emerging small-molecule approaches mark a paradigm shift from inhibition alone to targeted degradation, durable covalent engagement, and diagnostic–therapeutic hybrids. Future priorities include improving selectivity, biomarker integration, scalable manufacturing, and equitable global access.
- 4 June 2025
- Published by Sciencedomain International in Journal of Cancer and Tumor International
- Vol. 15 (3) , 256-270
Artificial Intelligence in Cancer Epigenetics: A Review of How Machine Learning Is Revealing New Patterns Beyond DNA Mutations
Beyond the human genetic codes, epigenetics also plays a key role in regulating how genes are expressed. While mutations or genes are known to be major causes of cancer, Epigenetic alterations, including DNA methylation, histone modifications, and non-coding RNAs, play critical roles in cancer progression by altering gene expression without involving DNA sequences, yet their complexity challenges traditional analytical approaches. This review aims to elucidate how digital technologies such as artificial intelligence (AI) and machine learning (ML) uncover novel epigenetic patterns beyond DNA mutations, enhancing cancer diagnosis, prognosis, and treatment. A comprehensive literature review was conducted, analysing peer-reviewed studies from rom recent reports on PubMed, Scopus, and bioinformatics databases, focusing on AI applications in several cancers such as breast, lung, and colorectal. Findings reveal that ML algorithms, including random forests, convolutional neural networks, and autoencoders, identify epigenetic signatures some of which are methylation patterns and histone modifications with up to 60–90% of cases with high accuracy. These signatures enable early detection, as demonstrated in a pancreatic cancer study achieving 87% sensitivity using ctDNA methylation. AI-driven multi-omics integration has so far uncovered synergistic interactions, improving metastasis prediction by 15–20% in ovarian cancer. Additionally, AI facilitates personalized epigenetic therapies, with models predicting response to histone deacetylase inhibitors in multiple myeloma with 90% accuracy. However, there are limitations to overcome. Some of which are data heterogeneity and model interpretability which exists in the nuances of machine systems. Ongoing research are currently exploring federated learning and explainable AI to address imminent challenges which would enhance generalizability and clinical trust. Future directions include single-cell epigenomics and AI applications in rare cancers to democratize precision medicine. Collaborative efforts among data scientists, clinicians, and biologists are essential to translate these insights into transformative cancer care.
- 4 June 2025
- Published by Sciencedomain International in Journal of Cancer and Tumor International
- Vol. 15 (3) , 256-270
Artificial Intelligence in Cancer Epigenetics: A Review of How Machine Learning Is Revealing New Patterns Beyond DNA Mutations
Beyond the human genetic codes, epigenetics also plays a key role in regulating how genes are expressed. While mutations or genes are known to be major causes of cancer, Epigenetic alterations, including DNA methylation, histone modifications, and non-coding RNAs, play critical roles in cancer progression by altering gene expression without involving DNA sequences, yet their complexity challenges traditional analytical approaches. This review aims to elucidate how digital technologies such as artificial intelligence (AI) and machine learning (ML) uncover novel epigenetic patterns beyond DNA mutations, enhancing cancer diagnosis, prognosis, and treatment. A comprehensive literature review was conducted, analysing peer-reviewed studies from rom recent reports on PubMed, Scopus, and bioinformatics databases, focusing on AI applications in several cancers such as breast, lung, and colorectal. Findings reveal that ML algorithms, including random forests, convolutional neural networks, and autoencoders, identify epigenetic signatures some of which are methylation patterns and histone modifications with up to 60–90% of cases with high accuracy. These signatures enable early detection, as demonstrated in a pancreatic cancer study achieving 87% sensitivity using ctDNA methylation. AI-driven multi-omics integration has so far uncovered synergistic interactions, improving metastasis prediction by 15–20% in ovarian cancer. Additionally, AI facilitates personalized epigenetic therapies, with models predicting response to histone deacetylase inhibitors in multiple myeloma with 90% accuracy. However, there are limitations to overcome. Some of which are data heterogeneity and model interpretability which exists in the nuances of machine systems. Ongoing research are currently exploring federated learning and explainable AI to address imminent challenges which would enhance generalizability and clinical trust. Future directions include single-cell epigenomics and AI applications in rare cancers to democratize precision medicine. Collaborative efforts among data scientists, clinicians, and biologists are essential to translate these insights into transformative cancer care.